Go offline with the Player FM app!
Recognition and Initial Management of ITP
Manage episode 324696144 series 3264057
In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.
Contributors:
Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts
Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota
Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.
Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.
90 episodes
Manage episode 324696144 series 3264057
In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.
Contributors:
Hanny Al-Samkari, MD
Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts
Christopher Nelson, ACNP-BC, MBA
Nurse Practitioner
Hematology and Oncology
Avera Cancer Institute
Avera St Luke’s Hospital
Aberdeen, South Dakota
Dr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.
Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.
90 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.